Vantage Point

Share this article:

I recently attended the PMRG conference in Phoenix, and came away with several realizations. While much of marketing research remains the same as it has for decades, with full-service marketing research organizations providing qualitative and quantitative research to pharma clients, several specialized offshoots of marketing research have begun to take on lives of their own, or at least morph significantly.

For example, getting access to physicians for participation in marketing research has always been a function performed, for certain projects, by specialized recruiting organizations. But increasingly, physician recruitment, especially for Internet research, has become a specialty function. Epocrates, through its handheld system, uses one approach to recruit physicians ad hoc, while other companies specialize in maintaining ongoing panels of docs who are willing to participate in projects.

Some companies, for example, now specialize in providing efficient ways of compensating physicians, while others have developed a specialty of identifying key opinion leaders for research and social marketing purposes. One of the largest areas of specialization is the measurement of sales force effectiveness, which has now become a multimillion-dollar business with the companies conducting such research either doing it exclusively, or at least having separate divisions that do this work.

At one end of the spectrum, one observes the consolidation of small and medium-sized marketing research organizations into multinational organizations with thousands of employees and a genuinely full range of services. At the other end, one encounters emerging entities that focus on a specific element of pharmaceutical marketing research, often, in fact, on elements that didn't exist a few years ago.

Richard Vanderveer is group CEO, GfK US Healthcare Companies

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Vantage Point

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Vantage Point

Vantage Point: Payers—the "experts" in healthcare research

Vantage Point: Payers—the "experts" in healthcare research

Access to payers is about knowledge, about understanding what they do in their jobs

Vantage Point: Determining "fair market value"

Vantage Point: Determining "fair market value"

Should pharma formulate a super matrix to determine the FMV of research incentives?

Vantage Point: Marketing Support for Clinical Trials

Vantage Point: Marketing Support for Clinical Trials

Pharmaceutical companies must provide robust marketing support for their clinical trials